Lab
Southeast Clinical Laboratories LLC
Southeast Clinical Laboratories LLC was paid $15.12M by Medicaid between Jan 2018 and Dec 2024, across 156 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 38% of everything it billed.
33Billing provider infoSOUTHEAST CLINICAL LABORATORIES LLC
BIRMINGHAM, AL 35222
BIRMINGHAM, AL 35222
33aNPI1730582594assigned 10/07/2014
33bProvider typeClinical Medical Laboratory
28Total paid$15.12M
24GClaims569,843
24DCodes billed156
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Alabama
Rank by total paid#8 of 61
Median peer was paid$46K
This provider vs. median332×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,377 | $843K | |
| 2019 | 59,988 | $1.26M | |
| 2020 | 54,602 | $1.45M | |
| 2021 | 109,941 | $3.97M | |
| 2022 | 107,315 | $3.25M | |
| 2023 | 106,865 | $2.43M | |
| 2024incomplete | 86,755 | $1.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 38% | 28,366 | 27,298 | $5.73M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.8% | 29,206 | 28,066 | $874K |
| 87581 | 5.1% | 28,826 | 27,816 | $766K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 5.0% | 21,824 | 21,046 | $760K |
| 87486 | 4.7% | 27,003 | 26,058 | $712K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 4.2% | 2,928 | 2,862 | $631K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.0% | 10,399 | 10,053 | $599K |
| 87081 | 3.0% | 63,490 | 60,762 | $455K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.7% | 7,734 | 7,502 | $405K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.2% | 16,672 | 16,069 | $336K |
| 80053 | Comprehensive metabolic panel | 1.8% | 25,769 | 24,520 | $273K |
| 83655 | 1.6% | 17,322 | 16,944 | $243K |
144 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 5,642 | $232K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 19,417 | $207K |
| 87507 | 1.3% | 1,022 | $201K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 22,488 | $198K |
| 80061 | Lipid panel | 1.3% | 15,418 | $192K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 20,765 | $182K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 6,364 | $157K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.0% | 1,478 | $152K |
| 87070 | <1% | 15,022 | $149K | |
| 84439 | <1% | 12,572 | $102K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,791 | $100K |
| 87077 | <1% | 11,150 | $84K | |
| 82607 | <1% | 4,710 | $68K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,292 | $61K |
| 87186 | <1% | 7,265 | $60K | |
| 82728 | <1% | 5,058 | $57K | |
| 87088 | <1% | 5,582 | $49K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 6,285 | $42K |
| 86665 | <1% | 1,082 | $40K | |
| 86235 | <1% | 339 | $40K | |
| 80055 | <1% | 631 | $39K | |
| 83516 | <1% | 2,962 | $36K | |
| 87631 | <1% | 501 | $31K | |
| 83550 | <1% | 3,831 | $31K | |
| 83540 | <1% | 5,024 | $31K | |
| 86038 | <1% | 2,039 | $27K | |
| 82746 | <1% | 2,462 | $27K | |
| 84481 | <1% | 1,776 | $24K | |
| 84403 | <1% | 901 | $24K | |
| 81001 | <1% | 6,509 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,368 | $23K |
| 82784 | <1% | 2,156 | $22K | |
| 82248 | <1% | 4,582 | $20K | |
| 87427 | <1% | 1,217 | $20K | |
| 83001 | <1% | 1,046 | $20K | |
| 86140 | <1% | 4,184 | $19K | |
| 86334 | <1% | 996 | $19K | |
| 80074 | <1% | 444 | $18K | |
| 82247 | <1% | 3,628 | $17K | |
| 84550 | <1% | 3,204 | $17K | |
| 83002 | <1% | 915 | $17K | |
| 85027 | <1% | 3,496 | $16K | |
| 85651 | <1% | 4,484 | $16K | |
| 86592 | <1% | 3,638 | $16K | |
| 84702 | <1% | 1,558 | $16K | |
| 86803 | <1% | 1,079 | $15K | |
| 82670 | <1% | 619 | $15K | |
| 86664 | <1% | 955 | $15K | |
| 83735 | <1% | 2,120 | $14K | |
| 82977 | <1% | 2,334 | $14K | |
| 86003 | <1% | 138 | $14K | |
| 82570 | <1% | 2,640 | $14K | |
| 87045 | <1% | 1,236 | $12K | |
| 83615 | <1% | 2,305 | $12K | |
| 82550 | <1% | 1,463 | $10K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 69 | $10K |
| 85660 | <1% | 2,068 | $9K | |
| 84165 | <1% | 730 | $9K | |
| 80069 | <1% | 1,198 | $9K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 101 | $8K |
| 84100 | <1% | 2,281 | $8K | |
| 83883 | <1% | 257 | $8K | |
| 86376 | <1% | 565 | $8K | |
| 83690 | <1% | 1,188 | $8K | |
| 86762 | <1% | 467 | $7K | |
| 85046 | <1% | 1,495 | $7K | |
| 82150 | <1% | 1,078 | $6K | |
| 86677 | <1% | 400 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 412 | $6K |
| 87640 | <1% | 340 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 149 | $5K |
| 87340 | <1% | 482 | $5K | |
| 86431 | <1% | 1,105 | $5K | |
| 84156 | <1% | 1,467 | $5K | |
| 82947 | <1% | 1,435 | $5K | |
| 82785 | <1% | 384 | $5K | |
| 82465 | <1% | 1,087 | $5K | |
| 83521 | <1% | 202 | $5K | |
| 87653 | <1% | 295 | $5K | |
| 84436 | <1% | 1,040 | $4K | |
| 87209 | <1% | 275 | $4K | |
| 82043 | <1% | 835 | $4K | |
| 86225 | <1% | 310 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 383 | $4K |
| 84146 | <1% | 185 | $4K | |
| 84153 | <1% | 238 | $4K | |
| 84144 | <1% | 191 | $3K | |
| 86850 | <1% | 500 | $3K | |
| 86663 | <1% | 228 | $3K | |
| 87046 | <1% | 1,104 | $3K | |
| 85610 | <1% | 663 | $3K | |
| 83880 | <1% | 113 | $3K | |
| 86769 | <1% | 45 | $3K | |
| 84480 | <1% | 262 | $3K | |
| 86706 | <1% | 210 | $2K | |
| 81003 | <1% | 874 | $2K | |
| 86800 | <1% | 149 | $2K | |
| 87177 | <1% | 275 | $2K | |
| 82085 | <1% | 179 | $2K | |
| 83090 | <1% | 108 | $2K | |
| 80076 | <1% | 240 | $2K | |
| 84479 | <1% | 691 | $2K | |
| 83021 | <1% | 79 | $2K | |
| 83525 | <1% | 164 | $2K | |
| 84155 | <1% | 541 | $2K | |
| 84999 | <1% | 238 | $1K | |
| 85014 | <1% | 463 | $1K | |
| 84402 | <1% | 44 | $1K | |
| 87329 | <1% | 115 | $1K | |
| 86900 | <1% | 466 | $1K | |
| 86901 | <1% | 446 | $1K | |
| 84270 | <1% | 43 | $1K | |
| 86200 | <1% | 85 | $984.95 | |
| 85730 | <1% | 181 | $933.97 | |
| 87338 | <1% | 59 | $747.19 | |
| 86481 | <1% | 12 | $738.33 | |
| 83970 | <1% | 14 | $663.00 | |
| 86364 | <1% | 67 | $530.52 | |
| 84450 | <1% | 86 | $496.25 | |
| 87529 | <1% | 98 | $464.57 | |
| 83718 | <1% | 64 | $457.28 | |
| 82378 | <1% | 18 | $408.00 | |
| 80164 | <1% | 26 | $374.00 | |
| 84160 | <1% | 73 | $354.35 | |
| 87324 | <1% | 28 | $354.30 | |
| 84466 | <1% | 26 | $333.17 | |
| 86696 | <1% | 17 | $320.26 | |
| 83993 | <1% | 19 | $304.34 | |
| 85018 | <1% | 106 | $292.80 | |
| 82627 | <1% | 13 | $280.07 | |
| 87040 | <1% | 33 | $276.01 | |
| 82274 | <1% | 15 | $251.37 | |
| 84478 | <1% | 45 | $231.00 | |
| 81015 | <1% | 107 | $199.23 | |
| 84460 | <1% | 30 | $196.00 | |
| 87102 | <1% | 24 | $188.98 | |
| 82533 | <1% | 12 | $183.70 | |
| 82340 | <1% | 12 | $70.87 | |
| 87210 | <1% | 12 | $38.59 | |
| 85008 | <1% | 343 | $9.89 | |
| 81511 | 0% | 194 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 10,324 | $0.00 |
| 80349 | 0% | 12 | $0.00 | |
| 81514 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOYD, NICOLE (CEO)